import { Link } from "react-router-dom";
import ArticleLayout from "@/components/ArticleLayout";

const Glp1Guide = () => (
  <ArticleLayout
    category="Education"
    title="Understanding GLP-1 Peptides: Semaglutide, Tirzepatide & Retatrutide"
    readTime="12 min read"
    date="February 2026"
    slug="understanding-glp1-peptides"
    description="Comprehensive guide to GLP-1 receptor agonists. Learn how these compounds work and their applications in research."
  >
    <p>GLP-1 receptor agonists represent some of the most researched peptides in metabolic science. Understanding how these compounds work, their differences, and proper research protocols is essential for anyone conducting related studies.</p>

    <h2>What is GLP-1?</h2>
    <p>GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring incretin hormone that plays a crucial role in glucose metabolism and appetite regulation. GLP-1 receptor agonists are synthetic peptides designed to mimic and enhance these effects.</p>

    <h3>Key Mechanisms</h3>
    <ul>
      <li>Stimulates insulin secretion in glucose-dependent manner</li>
      <li>Suppresses glucagon release</li>
      <li>Slows gastric emptying</li>
      <li>Reduces appetite through central nervous system effects</li>
      <li>Potential cardiovascular and neuroprotective properties</li>
    </ul>

    <h2>The Three Main Compounds</h2>

    <h3>💊 Semaglutide (Single Agonist)</h3>
    <ul>
      <li><strong>Mechanism:</strong> Pure GLP-1 receptor agonist</li>
      <li><strong>Half-life:</strong> ~7 days (weekly dosing)</li>
      <li><strong>Research dose range:</strong> 0.25mg - 2.4mg weekly</li>
    </ul>

    <h3>💊 Tirzepatide (Dual Agonist)</h3>
    <ul>
      <li><strong>Mechanism:</strong> GLP-1 + GIP receptor agonist</li>
      <li><strong>Half-life:</strong> ~5 days (weekly dosing)</li>
      <li><strong>Research dose range:</strong> 2.5mg - 15mg weekly</li>
    </ul>
    <p>Key characteristics: Dual mechanism provides enhanced metabolic effects in research. Generally shows stronger effects than single agonists. GIP pathway adds complementary insulin response.</p>

    <h3>💊 Retatrutide (Triple Agonist)</h3>
    <ul>
      <li><strong>Mechanism:</strong> GLP-1 + GIP + Glucagon receptor agonist</li>
      <li><strong>Half-life:</strong> ~6-7 days (weekly dosing)</li>
      <li><strong>Research dose range:</strong> 4mg - 12mg weekly</li>
    </ul>
    <p>Key characteristics: Newest and most complex mechanism. Glucagon pathway adds metabolic versatility. Early research shows potent effects but less established research base.</p>

    <h2>Comparing the Three</h2>

    <h3>Potency Hierarchy (Research Observations)</h3>
    <ol>
      <li><strong>Retatrutide:</strong> Most potent in metabolic studies</li>
      <li><strong>Tirzepatide:</strong> Strong effects, well-studied</li>
      <li><strong>Semaglutide:</strong> Effective, most established</li>
    </ol>
    <p>Note: Potency differences don't necessarily mean one is "better." Research applications vary.</p>

    <h3>Side Effect Profile (Research Context)</h3>
    <p>All three show similar side effect patterns in research:</p>
    <ul>
      <li>Gastrointestinal effects (most common)</li>
      <li>Nausea (especially during titration)</li>
      <li>Reduced appetite</li>
      <li>Potential site reactions</li>
    </ul>
    <p><strong>📊 Titration is Critical:</strong> All GLP-1 agonists require gradual dose escalation in research protocols. Starting at maximum doses significantly increases adverse reactions.</p>

    <h2>Research Dosing Protocols</h2>

    <h3>Semaglutide Titration Schedule</h3>
    <table>
      <thead><tr><th>Weeks</th><th>Dose</th></tr></thead>
      <tbody>
        <tr><td>1-4</td><td>0.25mg weekly</td></tr>
        <tr><td>5-8</td><td>0.5mg weekly</td></tr>
        <tr><td>9-12</td><td>1mg weekly (if needed)</td></tr>
        <tr><td>13+</td><td>Up to 2.4mg weekly (research maximum)</td></tr>
      </tbody>
    </table>

    <h3>Tirzepatide Titration Schedule</h3>
    <table>
      <thead><tr><th>Weeks</th><th>Dose</th></tr></thead>
      <tbody>
        <tr><td>1-4</td><td>2.5mg weekly</td></tr>
        <tr><td>5-8</td><td>5mg weekly</td></tr>
        <tr><td>9-12</td><td>7.5mg weekly (if needed)</td></tr>
        <tr><td>13+</td><td>10-15mg weekly (research maximum)</td></tr>
      </tbody>
    </table>

    <h3>Retatrutide Titration Schedule</h3>
    <table>
      <thead><tr><th>Weeks</th><th>Dose</th></tr></thead>
      <tbody>
        <tr><td>1-4</td><td>4mg weekly</td></tr>
        <tr><td>5-8</td><td>8mg weekly</td></tr>
        <tr><td>9-12</td><td>12mg weekly (research maximum)</td></tr>
      </tbody>
    </table>

    <h2>Storage & Handling</h2>
    <h3>Lyophilized (Powder) Form</h3>
    <ul>
      <li>Store at -20°C (freezer) for long-term</li>
      <li>Shelf life: 2-3 years when properly stored</li>
      <li>Protect from light</li>
    </ul>

    <h3>Reconstituted Form</h3>
    <ul>
      <li>Store at 2-8°C (refrigerator). Never freeze</li>
      <li>Use within 28-30 days</li>
      <li>Protect from light (use amber vials if possible)</li>
    </ul>

    <h3>Pre-Filled Pens</h3>
    <ul>
      <li>Refrigerate immediately upon receipt</li>
      <li>Never freeze</li>
      <li>Check expiration dates</li>
      <li>Shorter shelf life than powder form</li>
    </ul>

    <h2>Research Considerations</h2>

    <h3>When to Choose Semaglutide</h3>
    <ul>
      <li>Most established research base needed</li>
      <li>Conservative, well-documented approach preferred</li>
      <li>Single-mechanism studies desired</li>
      <li>Cost-effectiveness important</li>
    </ul>

    <h3>When to Choose Tirzepatide</h3>
    <ul>
      <li>Dual-mechanism research interests</li>
      <li>GIP pathway effects important to study</li>
      <li>Stronger effects desired in research model</li>
    </ul>

    <h3>When to Choose Retatrutide</h3>
    <ul>
      <li>Triple-mechanism research questions</li>
      <li>Cutting-edge metabolic research</li>
      <li>Glucagon pathway effects of interest</li>
      <li>Willing to work with newer compound</li>
    </ul>

    <h2>Safety Profile in Research</h2>
    <p>All three compounds show similar safety concerns in research settings:</p>
    <ul>
      <li>Most side effects are dose-dependent and transient</li>
      <li>Slow titration dramatically reduces adverse events</li>
      <li>GI effects typically resolve within 2-4 weeks</li>
      <li>No significant differences in safety between the three</li>
    </ul>
    <p><strong>⚠ Research Contraindications:</strong> Research should be avoided or done with extreme caution in models with: history of pancreatitis, medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or severe gastrointestinal disease.</p>

    <h2>Cost Comparison</h2>
    <ul>
      <li><strong>Semaglutide:</strong> Most affordable (most established)</li>
      <li><strong>Tirzepatide:</strong> Moderate pricing</li>
      <li><strong>Retatrutide:</strong> Higher pricing (newest)</li>
    </ul>

    <h2>Future of GLP-1 Research</h2>
    <ul>
      <li>Oral formulations under development</li>
      <li>Longer-acting variants being researched</li>
      <li>Combination therapies being explored</li>
      <li>Novel receptor targets under investigation</li>
    </ul>

    <h2>Conclusion</h2>
    <p>GLP-1 receptor agonists represent a fascinating area of metabolic research. Whether choosing Semaglutide's established profile, Tirzepatide's dual mechanism, or Retatrutide's triple action, proper dosing protocols and safety considerations are paramount.</p>
    <p>Always start with conservative doses, titrate slowly, and monitor research subjects carefully throughout protocols.</p>

    <p>Use our <Link to="/calculators">Dosing Calculator</Link> for weight-based recommendations and titration guidance for all three GLP-1 agonists.</p>
  </ArticleLayout>
);

export default Glp1Guide;
